Raymond James & Associates’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Raymond James & Associates’s Portfolio SLGC Stock Details SLGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,400	Closed	-$39K	–	4089
2023 Q4	$39K	Sell	15,400 -5,000	-25%	-$11.6K	﹤0.01%	3730
2023 Q3	$48.8K	Buy	20,400 +5,100	+33%	+$11.3K	﹤0.01%	3676
2023 Q2	$35.3K	Buy	15,300 +300	+2%	+$847	﹤0.01%	3731
2023 Q1	$38.3K	Buy	15,000 +1,930	+15%	+$5.53K	﹤0.01%	3755
2022 Q4	$32.8K	Buy	+13,070	New	+$36.5K	﹤0.01%	3752

Raymond James & Associates's SLGC Position: Q1 2024 in Review

Raymond James & Associates sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 15,400 shares — an estimated $39K sold.

Raymond James & Associates first reported a position in SLGC in Q4 2022 and held it in 5 quarters. The position peaked at $48.8K in Q3 2023. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

Raymond James & Associates reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
Raymond James & Associates sold 15,400 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $39K.
Raymond James & Associates first reported a position in SomaLogic, Inc. Class A Common Stock in Q4 2022 and held it in 5 quarters.
Raymond James & Associates's SomaLogic, Inc. Class A Common Stock position peaked at $48.8K in Q3 2023.
0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.